IL13 and Pruritus: This is underscored by the fact that clinical symptoms and pruritus in AD are significantly improved by the anti-IL-4 receptor α (IL-4Rα) antibody dupilumab, which inhibits both IL-13 and IL-4 signaling [20,21,22].